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Within the tumour microenvironment (TME) there is a cellular ‘tug-of-war’ for glutamine, the most abundant 
amino acid in the body. This competition is most evident when considering the balance between successful 
anti-tumour immune response and the uncontrolled growth of tumour cells that are addicted to glutamine. 
The differential effects of manipulating glutamine abundance in individual cell types is an area of intense 
research and debate. Here, we discuss some of the current strategies in development altering local glutamine 
availability focusing on inhibition of enzymes involved in the utilisation of glutamine and its uptake by cells in 
the TME. Further studies are urgently needed to complete our understanding of glutamine metabolism, to 
provide critical insights into the pathways that represent promising targets and for the development of novel 
therapeutic strategies for the treatment of advanced or drug resistant cancers. 

























Glutamine, the most abundant amino acid in the body, is a highly versatile precursor, contributing to several 
metabolic and biosynthetic pathways (1). The discovery that cancer cells rely on glutamine (obtained from the 
local microenvironment, synthesised or generated by autophagy) to fuel growth, was made as early as 1955 
(1–3). Glutamine is not a classically essential amino acid, as it can be synthesised by glutamine synthase from 
glutamate and ammonia and some tumours have been shown to use autophagy to break down proteins to 
release amino acids including glutamine (4,5). However, glutamine can be viewed as a conditionally essential 
amino acid for lymphocytes and many tumours, as these cells consume more glutamine than they can make 
and thus rely on its uptake from their environment (6,7). This is of particular relevance, as lymphocytes, 
especially activated T cells, are in direct competition with tumour cells for this vital nutrient. Indeed, patients 
whose tumours display signatures associated with high glutamine metabolism, and thus potentially restricting 
glutamine availability to the immune system, have poor overall survival rates (8,9). Therefore, the idea of 
manipulating tumour glutamine metabolism as a therapeutic strategy is an area of intense research. Whilst 
initial in vitro experimentation has been promising (10–12), systemic side effects in some early clinical trials 
have cautioned against reagents with broad activity (13–15). Here, we review some of the advances made to 
date and the most exciting current strategies in clinical trials for oncology.  
Glutamine and its metabolites 
 
Glutamine is largely obtained through the diet but can also be synthesised de novo through activity of 
glutamine synthase (1). Under conditions of nutrient starvation, glutamine can also be acquired through the 
autophagic break-down of macromolecules (1,16). Glutamine provides fuel for rapidly dividing cells, including 
tumour cells and lymphocytes and can become essential in these situations. These highly proliferative cells 
import or take up glutamine through cell surface transporters (17). Many nutrient transporters are 
overexpressed by tumour cells. For example, the alanine–serine–cysteine transporter 2 (ASCT2), otherwise 
known as SLC1A5, and SLC38A2 (SNAT2), are the primary transporters responsible for glutamine uptake in 
cancer cells (Figure 1) (2,17–20). 
  
Glutamine is indispensable for many intracellular biosynthetic and metabolic processes including the synthesis 
of nucleotides, hexosamines and other non-essential amino acids, maintaining redox balance, glycosylation, 
the production of extracellular matrix proteins and in epigenetic regulation (21–24). To enable glutamine to 
fuel the tricarboxylic acid cycle (TCA), cells require the mitochondrial enzyme glutaminase (encoded by GLS), 
which catalyses the conversion of glutamine to glutamate. The subsequent conversion of glutamate to 2-
oxalogluterate (α-ketoglutarate; -KG), can be achieved by two distinct pathways, either via 























isocitrate and citrate in the TCA cycle. Citrate can either remain in the TCA cycle to form malate or be exported 
to generate acetyl-CoA to fuel lipid metabolism (Figure 1). Malate can also be exported to generate pyruvate, 
coupled to the reduction of NADP
+
 to NADPH, the latter again fueling lipid metabolism. 
 
Additionally, glutamate can be exported from cells via the anti-porter SLC7A11 (xCT) in exchange for cystine 
(Figure 1). Cystine can then be reduced in the cell to cysteine, which is either metabolised further or can again 
be released when glutamate is taken up. T cells express very low levels of SLC7A11 (25) (and ImmPRes 
accessed here: http://immpres.co.uk/). Furthermore, this transporter has been described to be non-functional 
in T cells (26). In line with this, an approach to block SLC7A11 impairs glutamate/cystine exchange in tumour 
cells but with only a moderate influence on T cell function (27). Moreover, we speculate that blockade of 
SLC7A11 activity might even enhance T cell function in the tumour, as T cells are partially dependent on 
extracellular cysteine, taken up via SLC1A5 (Figure 1), to satisfy their demand. Only after activation do effector 
T cells express the enzyme cystathionase (CTH) (25,28) which would allow them to make cysteine from 
methionine. Thus T cells directly compete with highly proliferative tumour cells for these metabolites, as well 
as for glutamine (29).  
 
Glutamate is a signaling molecule in its own right, being a vital neurotransmitter in the central nervous system 
(26). Interestingly, T cells express two distinct receptors for glutamate sensing; metabotropic glutamate 
receptor 5 (mGlu5R) which is constitutively expressed and involved in restraining pro-inflammatory cytokine 
release and proliferation in naïve/resting T cells (30), and mGlu1R, which is only expressed upon activation of T 
cells. mGlu1R has been described as imparting an opposing and dominant effect over mGlu5R, thus supporting 
effector cytokine release, differentiation and proliferation (26) and may play a role in the inhibition of 
activation induced cell death (31). These findings therefore implicate glutamate (from the ongoing catabolism 
of glutamine) in the tumour microenvironment (TME) as a strong immunomodulator of T cell function. 
 
Glutamine uptake is enhanced in T cells upon T cell receptor (TCR) stimulation and is critical for their survival, 
proliferation and effector function (32,33). Increased expression of the glutamine transporters ASCT2 
(SLC1A5), SNAT1 (SLC38A1) and SNAT2 (SLC38A2) mediate elevated glutamine uptake in activated T cells 
(32,33) and expression of glutaminolytic enzymes is concomitantly increased (33). These changes are driven 
by costimulation, for example via CD28 signalling (33) and induction of Myc expression (10,34). Glutamine 
supports T cell function in a number of ways, including facilitating the uptake (via direct exchange) of other 
amino acids including leucine, which is a key activator of the cellular metabolic regulator mechanistic target of 
rapamycin (mTOR) (16,32). When T cells lack SLC1A5 or are cultured in glutamine-free media they fail to 
























Additionally, glutamine is used to fuel the TCA cycle, particularly in conditions where glucose availability might 
be limited, such as in the TME (36). Importantly, distinct immune cell subsets demonstrate differential reliance 
on glutamine, and are therefore likely to be impacted in different ways by its depletion in the TME. Recently, 
using cutting edge radiolabelled glucose and glutamine in vivo uptake studies Reinfeld et al. show that in the 
TME (on a per cell basis) tumour cells are the biggest consumers of glutamine, followed by myeloid-derived 
suppressor cells (MDSC), with immune cells including tumour associated macrophages (TAM) and T cells in 
comparison only taking up comparatively small amounts (37). Notably, in both mice and humans, glutamine 
deprivation favours the differentiation of regulatory T cells (TREG), which are immune-suppressive and highly 
proliferative in vivo (38–40). More recently, it was shown that by inhibiting the conversion of glutamine to 
glutamate it is possible to influence memory CD4
+
 T differentiation, particularly altering the balance between 
Th1 and Th17 CD4
+
 T cells (41). Furthermore, glutamine synthase inhibition also increases the accumulation of 
pro-inflammatory macrophages with the capacity to further enhance lymphocyte recruitment (42). Therefore, 
targeting tumour cell glutamine metabolism may result in pleiotropic effects which can be exploited to target 
additional cells present in the tumour microenvironment, including immune cell populations. 
 
Thus glutamine metabolism is emerging as an interesting target for cancer immunotherapy. Here we will 
introduce three approaches being evaluated for immunotherapeutic intervention, that harness the metabolic 
control of local glutamine levels to limit tumour cell growth and enhance anti-tumour T cell function. We will 
discuss the potential of each strategy in turn.  
  
1)  Inhibition of glutaminase (GLS) - a crucial step in the utilisation of glutamine
 
 
Many human cancers, including hepatocellular carcinoma, ovarian cancer, osteosarcoma, colorectal cancer 
and breast cancer are characterised by increased GLS expression - significantly correlating with patient survival 
(43–46). Similarly, elevated GLS expression, and its activity, is associated with high grade lesions and 
metastatic cancer (47). In particular, using data curated by The Cancer Genome Atlas, Edwards et al recently 
highlighted the inverse relationship between gene signatures associated with high levels of glutamine 
metabolism (based on expression of glutamine utilising enzymes and glutamine transporter expression) and 
anti-tumour T cell effector function in triple negative breast cancer. Similarly, overall survival rates are 
























The close connection between tumour cell growth, glutamine utilisation, GLS expression and the associated 
impact on T cell activation and effector function have led to targeting suppression of GLS with either small 
molecule inhibitors or genetic knockdown approaches. Promisingly, small molecule GLS inhibitors have been 
shown to exhibit anti-proliferative activity and reduce tumour burden (43,48,49) across a variety of tumours, 
including lymphoma, breast, pancreatic, non–small cell lung and renal cancers (9,10,48,50,51). In line with 
these clinical observations, the effector function of anti-tumour T cells is markedly improved if tumour cells 
lose GLS activity in vitro using cutting-edge techniques such as CRISPR-Cas9, attributable to a reduction in 
tumour-cell driven glutamine depletion and a concomitant increase in local glutamine availability to T cells (8).  
 
Many potent small molecule inhibitors have been developed to target GLS disturbing further aspects of 
glutamine metabolism, including two compounds of note - bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-
yl)ethyl sulfide (BPTES) and CB-839 (52). Although BPTES showed initial promise in vitro inhibiting tumour cell 
proliferation, its advanced clinical development has been limited due to ongoing issues with bioavailability and 
poor drug solubility (53). To improve solubility, a number of BPTES derivatives have been developed including 
the more potent, and selective inhibitor, CB-839 (49,54). CB-839 has been reported to have broad 
antiproliferative activity against both solid tumours and hematological malignancies, including difficult to treat, 
triple-negative breast cancer and pancreatic ductal adenocarcinoma in vitro models (49,55,56). The 
therapeutic addition of CB-839 led to a marked decrease in tumour cell glutamine consumption, glutamate 
production and several TCA intermediates. Importantly, numerous clinical trials using CB-839 as either a 
monotherapy or as a combination therapy are ongoing (detailed on the NIH website: 
https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/glutaminase-inhibitor-cb-839), 
and time will tell the in vivo impact on immune cell function. 
 
2)  Broad targeting of glutamine metabolism  
 
As introduced in the previous section, many of the initial efforts to target glutamine in oncology focused on 
the first step of glutaminolysis with specific GLS inhibitors (10). Although these inhibitors demonstrated 
efficacy in vitro, it has become increasingly clear that GLS inhibition is much less effective in vivo (56). 
Therefore, as an alternative to inhibiting just one enzymatic step, drugs that comprehensively manipulate 
glutamine metabolism more broadly such as the glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) that 
inhibits a range of glutamine-requiring enzymes including GLS have been developed (57). Early studies over 50 
years ago reported the ability of DON to potently inhibit tumour cell growth, and to simultaneously alter the 
metabolic landscape of the TME. However, the full clinical development of DON was abandoned after early 
























More recently the development of a series of pro-drugs based on DON, designed to mitigate overt toxicity, 
have offered hope for clinical translation. The most promising of which is a pro-drug JHU-083. JHU-083 
markedly enhances endogenous anti-tumour immunity, with significant improvements in the overall survival 
of tumour-bearing mice (58). Interestingly, Leone et al have recently shown that treatment with JHU-083 
increases the number of tumour-specific CD8
+
 T cells infiltrating the TME, these T cells are more proliferative, 
and appear to be robustly activated and less exhausted with improved effector functionality (58), in line with 
another finding that transient GLS-inhibition increases Tbet expression, skewing responses towards Th1 and 
increased cytotoxic T cell activity (41). 
 
Importantly, the tumour specific CD8
+
 T cell compartment adapts to the metabolic environment of glutamine 
blockade by switching their ‘metabolic profile’, instead generating high levels of acetyl-CoA to fuel the TCA 
cycle by upregulating acetate metabolism rather than maintaining an over-reliance on glutaminolysis (58), 
while tumour cells largely failed to do the same.  
 
Beyond the initial study by Leone et al highlighting the differential ability of JHU-083 to disable tumour cells 
and enhance T cell function, Oh et al further report that therapeutic targeting of glutamine metabolism with 
JHU-083 not only prevents tumour cell growth but dramatically changes the cellular composition of the TME. It 
seems that JHU-083 can prevent the generation, recruitment and reprogramming of immunosuppressive 
myeloid cell populations, significantly reducing the number of suppressive MDSC entering the TME. 
Mechanistically JHU-083 induces either the local apoptosis of MDSC population and/or promotes their 
differentiation into mature, pro-inflammatory macrophages, with an improved capacity for antigen 
presentation (59). 
 
Further support for the clinical development of pro-drugs such as JHU-083, comes from the ability of JHU-083 
to prevent the development of metastatic disease in murine models. Treatment of tumour-bearing mice with 
JHU-083 showed an altered metabolic milieu at distinct metastatic sites as well as that within the primary 
tumour. Secondly, and perhaps more relevant to the current therapeutic landscape is the ability of JHU-083 to 
enhance the therapeutic efficacy of immune checkpoint blockade in immunotherapy-resistant tumours (59).  
 
Taken together, these data provide a strong preclinical rationale for strategies antagonising glutamine 
























3) Specific manipulation of glutamine transporter activity 
 
There is little doubt that manipulating glutamine metabolism in the TME is an encouraging therapeutic 
strategy in the treatment of certain cancers, including triple negative breast cancer. In parallel, another 
strategy under consideration is the blockade of cellular glutamine uptake, which will also impact additional 
activities of glutamine beyond its metabolism, including facilitation of the uptake of other amino acid 
transporters that require glutamine antiport (for example via, SLC7A5; LAT1, Figure 1). Three years ago, 
Schulte et al first demonstrated the use of the glutamine transporter inhibitor, V-9302 a potent small molecule 
antagonist designed to target ASCT2 (60). Following just a single dose of V-9302, glutamine uptake into 
malignant cells of mice bearing tumour HCC-1806 cell-line xenografts reduced by up to 50%, attenuating 
tumour cell growth and proliferation (60). Importantly, this study raised the possibility that the therapeutic 
benefit of V-9302 was tumour-cell specific, and its use in vivo may ‘protect’ T cell immune surveillance. 
 
More recently understanding the utility of V-9302 in oncology has been taken a step further. A study by 
Edwards et al has shown that while limiting the growth of orthotopic E0771 tumours, V-9302 increased the 
infiltration of CD8
+
 T cells into the TME, that were more activated and exhibited improved cytolytic and non-
cytolytic effector function. Additionally, treatment with V-9302 concomitantly altered the predominance of 
CD4
+
 T cell subsets, increasing the number of Th1 cells producing the anti-tumour effector molecule IFNγ
+
 in 
the TME. Key to the metabolic flexibility of these anti-tumour T cells, was their ability to adapt, with the 
compensatory upregulation of alternative glutamine transporters such as SLC6A14, that was not seen on the 
tumour cells, allowing for superior anti-tumour T cell responses, while curtailing tumour cell growth (8).  
 
Taken together, the tumour-selective blockade of glutamine uptake represents a promising approach to 
combat cancer, providing a two-pronged attack, boosting anti-tumour immune responses while crippling 
tumour cell metabolism. 
 
Combining glutamine manipulation with check-point blockade  
Recent findings have shown that limiting glutamine availability can lead to increased expression of PD-L1 on 
tumour cells (61,62) and a concomitant increase in expression of the death ligand Fas on T cells. Furthermore, 
ligation of both checkpoint inhibitors PD-1 and CTLA-4 significantly impairs activation-induced upregulation of 























a key driver of glutamine metabolism in these cells. Thus, while increased PD-L1 expression on tumour cells 
can suppress the T cell response, it also makes cancer cells amenable to checkpoint blockade therapy with PD-
1/PD-L1 inhibition promoting tumour cell susceptibility to T cell mediated killing (61,63).  
 
Detection of tumours amenable to glutamine manipulation 
It is likely that the above discussed therapies will benefit some patients more than others, due to individual 
differences in glutamine metabolism and tumour heterogeneity. To allow better prediction of therapeutic 
success, before starting therapy, glutamine addicted tumours could be revealed by positron emission 
tomography (PET) scans making use of glutamine tracers, a strategy currently being tested (64,65). Soon this 
might allow us to establish not only how glutamine is distributed, both systemically and within the TME, but 
also how effectively a specific drug is decreasing glutamine uptake by cancer cells. This imaging strategy is 
currently being researched using PET tracers (for example using 11C-glutamine (65)) to identify cancerous 
tumours by detecting any increases in the glutamine metabolism rate, which are predicted to be higher 
compared with that of normal, healthy cells in the body. The Vanderbilt Center for Molecular Probes is hosting 
five clinical trials designed to test the effectiveness of tracers including 11C-Glutamine and 18F-FSPG, a new 
radiopharmaceutical used in PET scans, tracing various types of tumours, including lung, liver, ovary and colon 
cancer. As introduced earlier, in vivo use of radiolabelled glucose and glutamine has revealed that tumour cells 
are the greatest consumers of glutamine, whilst MDSC are the greatest consumers of glucose (on a cell per cell 
basis) (37). Of note, tumour cells outnumber all other cells in the TME and therefore represent the net major 
consumers of both nutrients (37). Tumour infiltrating T cells appear to take up broadly equivalent amounts of 
glucose and glutamine; this may indicate plasticity or a retained capacity to balance metabolic pathways, as 
has been demonstrated in previous in vivo labelling infection studies (36,66). Altogether, these studies support 
the notion that inhibiting glutamine uptake or metabolism would preferentially target tumour cells and 
associated suppressor cells.  
Tracing glutamine uptake could offer additional advantages, as some cancers, such as gliomas in the brain, are 
difficult to detect using established glucose tracing, since the healthy brain tissue itself is a major consumer of 
glucose thereby effectively hiding the malignant tissue; use of glutamine tracing here demonstrated 
experimental success (67).  
Future outlook 
Although targeting glutamine metabolism represents a promising strategy for the clinical design of therapeutic 
agents, several challenges remain. Since glutamine is essential for cellular proliferation, function and 
ultimately, host defense, there is the potential for unwanted side effects by targeting glutamine or associated 























that restrict glutamine metabolism. For example, high expression of GLS can drive glutamine synthesis from 
glutamate, maintaining cell proliferation during glutamine deprivation (68). It is therefore becoming 
increasingly apparent that future therapeutic strategies should be devised in the context of the metabolically 
hostile TME. For example, glutamine deficiency may be a critical barrier to using CAR T cell therapy for treating 
solid tumours; pre-adaptation of CAR T cells in conditions which reproduce the in vivo metabolic environment 
of tumours may improve anti-tumour responses in vivo. Indeed, recent evidence suggests that pre-adaptation 
to glutamine deprivation in vitro enhances CD8
+
 T cell responses when later adoptively transferred in vivo, 
although the mechanisms behind this are not yet completely understood (41,69,70).  
 
One further complexity is the potential for epigenetic modulation in response to the TME. Metabolism and 
epigenetic regulation of T cells are heavily intertwined; epigenetic modifiers utilise products of key cellular 
metabolic processes as either cofactors or substrates, and regulation of the epigenetic landscape can directly 
influence cellular metabolism (71,72). In particular, disrupted glutamine metabolism results in depletion of α-
KG
 4
, which in turn influences the epigenetic landscape of CD8
+
 T cells in the tumour microenvironment. For 
example, succinyl-CoA derived from α-KG oxidation provides substrate for histone  succinylation (74), a 
process which is tightly linked to tumour cell proliferation. In addition glutamine-derived α-KG is crucial for the 
activity of histone and DNA demethylation enzymes such as Jumonji N/C-terminal domain (JmjC) and ten-
eleven translocation (TET) enzymes (75), which are necessary for anti-tumour immunity. Although this 
interplay between glutamine metabolism, epigenetic regulation and the tumor microenvironment remains to 
be fully elucidated, combined epigenetic-directed and metabolic therapies might hold potential to improve 
current cancer therapies such as checkpoint blockade. In line with this, a recent study demonstrated the 
potential for dietary intervention, showing that glutamine supplementation, rather than the nutrient-limiting 





In conclusion, further studies in anticipation of a complete and robust understanding of glutamine metabolism 
in tumour and immune cells within the TME context is of the utmost importance, as it provides valuable 
insights into the pathways that could be targeted for the development of novel therapeutic strategies for the 



























Glutamine is taken up into cells via glutamine transports including SLC1A5 (ASCT2), SLC38A2 (SNAT2). Inside 
the cell glutamine can serve as a substrate for various pathways, such as the synthesis of nucleotides. 
Glutamine is converted by cytosolic and mitochondrial glutaminases to glutamate a substrate for conversion 
by aminotransferase or glutamate dehydrogenase to 2-oxalogluterate, which enter the TCA cycle, for the 
generation of ATP, or the production of acetyl-CoA and NADPH, both of which can fuel lipid metabolism or 
generate pyruvate. Glutamate further contributes as a precursor to the generation of the anti-oxidant 
glutathione and amino acids proline, alanine and aspartate. Glutamate can be exported from the cell to allow 
uptake of cystine, through the antiporter SLC7A11 (xCT). Other essential amino acids, including methionine, 
leucine and tryptophan are brought into the cell through the anti-porter SLC7A5, which uses glutamine as the 
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